Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer | MicrobiomeTrials← Back to trialsNCT07636798
Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-06Est. Completion: 2029-03
Enrollment target: 20 participants Locations- Study Chair Liu Chang , West China Hospital, Chengdu, Sichuan 610041, Chengdu, Sichuan, China
Other microbiome trials you might be interested in
Previously Treated, AdvancedBiliary Tract Cancers
This study aims to evaluate the safety and preliminary efficacy of anlotinib combined with cadonilimab and PULSAR in pre…
Chengdu, ChinaEst. completion Jun 30, 2027
Gallbladder Malignant Neoplasm
In our previous work, we found three types of bacteria in stool samples from South American patients with gallstones lin…
Cochabamba, BoliviaCompleted Jan 31, 2026